Wilmington Healthcare appoints new director to lead cloud-based healthcare customer intelligence tool
April 1, 2022 | NHS, Promotion, healthcare
Paul Rowe to lead intelligence tool that allows Industry to gain the complete picture of their changing NHS customer base and employ precision planning to access target customers and markets.
Wilmington Healthcare, which provides data, insight and intelligence for pharmaceutical, life sciences and medtech companies, healthcare charities and other NHS suppliers, has appointed Paul Rowe as Solution Director for the company’s Investigator XD product.
With more than 25 years’ experience of sales, marketing and training roles within the pharmaceutical industry, Paul will be responsible for the continuous development of Wilmington Healthcare’s Investigator XD platform as he brings together the company’s unrivalled, unique healthcare data and insight solutions into one cloud-based intelligence tool.
Paul is promoted from the role of Head of Sales at Wilmington Healthcare which he has held for nearly three years. Prior to this Paul has successfully held roles at Daiichi Sankyo and Bayer.
Paul says: “This is an exciting time at Wilmington Healthcare as we integrate our unrivalled data sources and information into one healthcare intelligence tool. We know ‘who’s who’ in the new NHS landscape and what their priorities and focus are better than anyone. And through our powerful insights platform we are able to inspire clients to transform their engagement with NHS customers – at a System, Place and Neighbourhood level – while identifying competitor vulnerability.
“We’re offering the capability to access the most powerful 360 degree view of the System all the way through to the individual customer. By truly integrating System objectives and pressure points, medicines management influences, prescribing decisions and patient outcomes, we are enabling the industry to maximise their market access. This rich data source is complemented by detail of the influential stakeholders, key influencers and opinion leaders across the new landscape in addition to the critical data detailing community demographics and social deprivation to help Industry work with NHS customers to tackle health inequalities and improve population health across care pathways.”
Jonathan Carney, Director of Insights and Key Account Management at Wilmington Healthcare, says: “Seismic shifts in the way the NHS is organised is directly impacting the way it will work with the life science and medtech sectors. This demands a rethink by Industry of the traditional key account management model and NHS customer intelligence tools if they wish to successfully engage, through tailored conversations, in this new environment.
“We are delighted that Paul is leading the next phase of our customer intelligence offering as we work with innovation to ensure that clients have the insight and intelligence to transform their relationships with health and social care partners into credible collaborations.”
For more information about Wilmington Healthcare’s insight and intelligence offer, please visit: https://wilmingtonhealthcare.com/what-we-do/healthcare-insight/
Company Details
Latest Content from Wilmington Healthcare
Wilmington Healthcare launches new platform to map the formulary landscape
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
Wilmington Healthcare appoints new Head of Digital
Wilmington Healthcare, which provides data, insight and intelligence for pharma and medtech companies, has appointed Pfizer’s former UK Digital Marketing Manager, Mikko Figura, as Head of Digital.In his new role,...
How has the pandemic reshaped the NHS in 2020?
Oli Hudson, of Wilmington Healthcare, explores the major changes that have occurred across the NHS as key aspects of the Long Term Plan are rolled out at speed.
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset
How can pharma align its brand strategy with the NHS Reset?
Oli Hudson, of Wilmington Healthcare, explores how pharma should respond to plans to ‘reboot’ the NHS during the covid recovery era
Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs
White paper helps industry navigate new NHS roadmap
New report shows how pharma can support the NHS in the Covid-19 recovery era
Covid-19 drives change in long-term conditions management
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home
Covid-19: how is it impacting on the NHS Long-term Plan?
Oli Hudson and Paul Midgley, of Wilmington Healthcare, explain how coronavirus has expedited some parts of the plan but put others in jeopardy
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it